Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose:
The new ACR/EULAR remission criteria were proposed to predict favorable outcome in patients with rheumatoid arthritis (RA).
To evaluate the functional disability and quality of life (QOL) in patients with RA who achieved the ACR/EULAR remission criteria compared to that in patients who achieved 28-joints disease activity score (DAS28) remission in 1 year in a large daily practical observational cohort, IORRA.
Methods:
Patients who had moderate or high disease activity according to simplified disease activity score (SDAI) in April 2010 survey were extracted. Functional disability and QOL was assessed by the validated Japanese version of Health Assessment Questionnaire (J-HAQ) score and the European QOL-5 dimension (EQ-5D) acore, respectively. The disease activity after 1 year in each patient was assessed by SDAI and DAS28. The mean changes of progression of J-HAQ and EQ-5D scores in 1 year in each patient were calculated for the patients achieving remission criteria defined by SDAI or DAS28, respectively. The factors associated with achieving SDAI remission were evaluated by multiple regression analysis.
Results:
Among a total of 5,587 patients participated in the IORRA cohort in April 2010, 1,307 (23.4%) patients had high or moderate disease activity assessed by SDAI. In these patients, 85.7 % were female, and median age was 62.2 years and RA duration was 13 years. After 1 year, 11.7% and 16.9% patients achieved SDAI remission and DAS28 remission, respectively. The progression of J-HAQ score in 1 year was -0.30 + 0.49 in patients who achieved SDAI remission and -0.05 + 0.35 in patients who didn’t (p<0.001), whereas -0.26 + 0.47 in patients who achieved DAS28 remission and -0..05 + 0.35 in patients who didn’t (p<0.001). The odds ratio (OR) for non-progression of functional disability by achieving SDAI remission was 2.79 (95% confidence interval (CI), 1.70-4.59), whereas that by achieving DAS28 remission was 1.96 (95% CI, 1.34-2.86). The progression of QOL score in 1 year was 0.165 + 0.162 in patients who achieved SDAI remission and 0.028 + 0.123 in who didn’t (p<0.001), whereas 0.129 + 0.169 in patients who achieved DAS28 remission and 0.028 + 0.121 in patients who didn’t (p<0.001). The OR for non-deterioration of QOL by achieving SDAI remission was 2.90 (95% CI 1.62-5.23), whereas that by achieving DAS28 remission was 2.11 (95% CI 1.35-3.29). The factors associated with achieving SDAI remission in 1 year were disease duration (OR 0.96, 95%CI 0.93-0.98), baseline physical function (OR 0.52, 95%CI 0.39-0.70) and biologics initiation within 6 months (OR 3.70, 95%CI 2.05-6.54).
Conclusion:
Achieving SDAI remission has more impact on both better physical function and improved QOL than achieving DAS28 remission.
Disclosure:
Y. Shimizu,
None;
A. Nakajima,
None;
E. Inoue,
None;
E. Tanaka,
None;
A. Kobayashi,
None;
Y. Seto,
None;
S. Momohara,
None;
A. Taniguchi,
None;
H. Yamanaka,
UCB Pharma, Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,
2,
UCB Pharma, Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,
5.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/functional-disability-and-quality-of-life-are-more-likely-improved-in-patients-with-rheumatoid-arthritis-who-achieved-the-new-acreular-remission-criteria-compared-to-das28-remission-in-daily-practice/